Evidence map›Paper›PMID 35135913›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis.

Hiroyuki Murakami, Masanori Makita, Tatsunori Ishikawa, Takanori Yoshioka, Keina Nagakita, Yoko Shinno, Tadashi Yoshino, Yoshinobu Maeda, Kazutaka Sunami

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Hiroyuki MurakamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Japan.
Masanori MakitaDepartment of Hematology, National Hospital Organization Okayama Medical Center, Japan.
Tatsunori IshikawaDepartment of Hematology, National Hospital Organization Okayama Medical Center, Japan.
Takanori YoshiokaDepartment of Hematology, National Hospital Organization Okayama Medical Center, Japan.
Keina NagakitaDepartment of Pathology, National Hospital Organization Okayama Medical Center, Japan.
Yoko ShinnoDepartment of Pathology, National Hospital Organization Okayama Medical Center, Japan.
Tadashi YoshinoDepartment of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
Yoshinobu MaedaDepartment of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Japan.
National Hospital Organization · JPOkayama Medical Center · JPOkayama University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 74-year-old man was admitted to our hospital because of systemic lymphadenopathy, weight loss, and a fever at night that had persisted for approximately 1 month. Blood tests revealed extreme peripheral blood plasmacytosis and hypergammaglobulinemia. A lymph node biopsy showed angioimmunoblastic T-cell lymphoma (AITL). Based on the history of methotrexate (MTX) administration, the established diagnosis was MTX-associated lymphoproliferative disorder (MTX-LPD). After MTX was discontinued, the lymphadenopathy spontaneously regressed and the plasmacytosis disappeared. He had no disease progression for three years. We found that AITL as an MTX-LPD can cause plasmacytosis, and the prognosis of this disease may not be poor.

Indexed as

Immunoblastic LymphadenopathyLymphadenopathyLymphoma, T-CellLymphoproliferative DisordersAgedHumansMaleMethotrexateMethotrexateangioimmunoblastic T-cell lymphomamethotrexateMTX-associated lymphoproliferative disorderplasmacytosis

Identifiers

PMID35135913
PMCPMC9492481
OpenAlexW4210846260

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.